The European Medicines Agency (EMA) has green a green signal to GlaxoSmithKline for its once-weekly diabetes drug albiglutide.
The Committee for Medicinal Products for Human Use (CHMP) of has recommended in a positive way to the drug which is marketed under the brand name Eperzan.
Albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an investigational biological product that treats type 2 diabetes. It is designed for once-weekly subcutaneous dosing.
However, the GlaxoSmithKline (GSK) has said that a final decision was anticipated later this quarter.
EMA say, Albiglutide is approved for those patients who allergic to the widely-used metformin. Moreover, it is also used as an add-on therapy when other glucose-lowering products do not provide adequate glycaemic control.
The committee gave its nod following an evaluation of a comprehensive global program of studies involving over 5,000 patients.
In 2013, the regulators in the United States have deferred the approval decision on the drug till April 15.
